Just days ago, GlaxoSmithKline signed the first big deal with the Francis Crick Institute. And now a high-profile examination of the state of play of partnering in academic research circles, the Dowling Report, says Glaxo is the single largest collaborator with academia in the U.K., for any industry.
The initiative sees the Big Pharma team up with Vida Health to push an app that helps people recover from heart attacks by guiding them through the weeks and months after the event, Fortune reports.
AstraZeneca's Iressa is back. After four years off the U.S. market, the lung cancer fighter has picked up an FDA approval as a first-line lung cancer therapy, specifically for patients whose tumors test positive for certain EGFR mutations, the company said Monday.
AstraZeneca has been working hard lately to get its sales on an upward track, a feat it expects to achieve in the not-too-distant future. In the meantime, though, it's looking to plug the holes, and it struck a divestment deal Thursday to help do just that--and streamline its focus, too.
When it comes to which brands spent the most on doctor payments, 2014 crowned a new king--and that's diabetes drug Bydureon.
AstraZeneca and Ironwood Pharmaceuticals say their Phase III study for linaclotide, conducted primarily in China among patients with irritable bowel syndrome with constipation, came through on all primary and secondary endpoints.
AstraZeneca and Teva Pharmaceutical's Cephalon are forking over more than $50 million to settle claims by the U.S. government that the companies underpaid rebates owed through Medicaid prescription drug programs, the latest chapter in the Department of Justice's crackdown on Medicaid and Medicare fraud.
Bristol-Myers Squibb has won a court verdict to uphold its patent on Sprycel (dasatinib), fending off a challenge, for now, from India's BDR Pharmaceuticals, which sought a compulsory license to make the drug and sell it at a lower cost domestically. But other challenges abound, including one by little-known Lee Pharma for AstraZeneca's Onglyza.
Greeks rejected their proposed bailout over the weekend, but so far drugmakers say they're continuing to ship products to the country. Greek hospitals already owe pharma more than $1 billion, and the lack of a fiscal deal means the bills will keep stacking up. Bank closures could complicate other payments.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.